Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
SR One Capital Management is a venture capital firm founded over a decade ago, with a focus on biotechnology investments. The firm operates from two key locations: Redwood City, California, and London, United Kingdom. SR One partners with founders and entrepreneurs to translate innovative science into effective medicines, emphasizing companies with strong underlying fundamentals and clearly defined development pathways.
Over the years, SR One has established itself as a significant player in the life sciences sector, focusing on various stages of company development. The firm has built a diverse portfolio that reflects its commitment to supporting groundbreaking therapies across multiple disease areas. Its transatlantic presence allows it to tap into high-quality scientific opportunities in both North America and Europe.
SR One Capital Management invests in biotechnology companies across a range of sectors, including cardiometabolic diseases, oncology, immunology, infectious disease, rare diseases, renal, and neuropsychiatry. The firm employs a back-and-build investment strategy, which allows it to support companies at various stages of development, from clinical to preclinical. This approach enables SR One to provide entrepreneurs with essential resources, including human, intellectual, and financial support.
The firm targets investments in both private and public companies, focusing on those with strong fundamentals and clear development pathways. SR One's transatlantic presence enhances its ability to access high-quality science and investment opportunities, making it a valuable partner for biotech entrepreneurs.
SR One Capital Management has a notable portfolio that includes a variety of innovative biotechnology companies. Key portfolio companies include:
Simeon George, MD - CEO & Managing Partner. Simeon has extensive experience in the biotechnology sector, having led numerous successful investments and strategic initiatives.
Rajeev Dadoo, PhD - COO & Managing Partner. Rajeev brings a strong scientific background and operational expertise to the firm, focusing on enhancing portfolio company performance.
Jill Carroll - Partner. Jill has a proven track record in venture capital and a deep understanding of the biotech landscape.
Jake Nunn - Partner. Jake specializes in identifying and supporting innovative biotech companies, leveraging his extensive network in the industry.
Philip Habib - Head of Capital Partnering. Philip focuses on building strategic partnerships and enhancing capital access for portfolio companies.
Sasha Keough - General Counsel & Chief Compliance Officer. Sasha ensures that the firm adheres to all regulatory requirements and best practices in venture capital.
James Macadam - Chief Financial Officer. James oversees the financial operations of the firm, ensuring sound financial management and reporting.
What investment criteria does SR One Capital Management prioritize?
SR One focuses on biotechnology companies with strong fundamentals and clearly defined development pathways. They seek to partner with founders who are translating innovative science into effective medicines.
How can founders pitch to SR One?
Founders can reach out via email to initiate a conversation. It is advisable to include a detailed overview of the company, its technology, and the specific funding needs in the initial communication.
What stages of investment does SR One engage in?
SR One invests across multiple stages, including pre-seed, seed, seed-plus, Series A, Series B, and Series C. This allows them to support companies at various points in their development.
What geographic areas does SR One focus on?
The firm has a transatlantic presence, primarily focusing on opportunities in North America and Europe. This geographic scope enables them to access high-quality scientific advancements and investment opportunities.
What types of companies does SR One typically invest in?
SR One invests in biotechnology companies across sectors such as cardiometabolic diseases, oncology, immunology, infectious disease, rare diseases, renal, and neuropsychiatry. They are particularly interested in companies with innovative approaches to addressing diseases.
What is SR One's involvement post-investment?
SR One provides ongoing support to portfolio companies, leveraging its extensive network and expertise to assist in the development of novel therapeutics and navigating the complexities of the biotech landscape.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.